Shots:

• Eli Lily acquires Loxo Oncology- in all stock transaction for $8B. Loxo to receive $235/share in cash making $8B as total deal value- including premium based on its last day closing share price value
• The focus of the acquisition is to utilize Loxo’s approved oncology portfolio for patients with genomically defined cancers. The acquisition is expected to close in Q1’19
• Vitrakvi is an oral TRK inhibitor developed in collaboration with Bayer- targeted for specific genetic abnormality and has also received FDA approval. LOXO-292 is an oral RET inhibitor indicated for targeting cancers with alterations to the rearranged during transfection (RET) kinase. LOXO-305 & LOXO-195 is an oral P-I/II BTK & TRK inhibitor respectively

Ref: Lilly | Image: Eli Lilly